This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kennedy, R. C. Articles by Bright, R. K. Search for Related Content PubMed PubMed Citation Articles by Kennedy, R. C. Articles by Bright, R. K.

CD4+ T Lymphocytes Play a Critical Role in Antibody Production and Tumor Immunity against Simian Virus 40 Large Tumor Antigen¹

Department of Microbiology and Immunology, Texas Tech University Health Science Center, Lubbock, Texas 79430

The role of CD4+ T lymphocytes in antitumor immunity has been largely attributed to providing signals required for the priming of MHC class I-restricted CD8+ cytotoxic T lymphocytes, and CD8+ cytotoxic T lymphocytes are thought to serve as the predominant mediators of tumor killing in vivo. We decided to evaluate the role of T lymphocyte subsets in tumor immunity induced by recombinant SV40 large tumor antigen (Tag) within an experimental murine pulmonary metastasis model of SV40 Tag-expressing tumors. Studies in BALB/c mice used in vivo depletion of either CD4+ or CD8+ T cells in the induction phase of the immune response to SV40 Tag. These studies indicate that CD4+ T cells but not CD8+ T cells were critical in the production of antibodies to SV40 Tag and in tumor immunity as the result of recombinant SV40 Tag immunization. On the basis of the predominance of the IgG1 isotype in the antibody response to SV40 Tag immunization, Th2 type CD4+ T cells appeared to be involved. SV40 Tag immunization was not as effective in the induction of tumor immunity in therapeutic modalities when compared with the prophylactic setting. Our results suggest that CD4+ T cells, along with antibody responses, play a role in the induction of tumor immunity to a viral-encoded tumor antigen.

This article has been cited by other articles:

				D. B. Lowe, M. H. Shearer, C. A. Jumper, R. K. Bright, and R. C. Kennedy Fc{gamma} Receptors Play a Dominant Role in Protective Tumor Immunity against a Virus-Encoded Tumor-Specific Antigen in a Murine Model of Experimental Pulmonary Metastases J. Virol., February 1, 2007; 81(3): 1313 - 1318. [Abstract] [Full Text] [PDF]

				J. Dengjel, M.-D. Nastke, C. Gouttefangeas, G. Gitsioudis, O. Schoor, F. Altenberend, M. Muller, B. Kramer, A. Missiou, M. Sauter, et al. Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas. Clin. Cancer Res., July 15, 2006; 12(14): 4163 - 4170. [Abstract] [Full Text] [PDF]

				P. Li, N. Wang, D. Zhou, C. S. K. Yee, C.-H. Chang, R. R. Brutkiewicz, and J. S. Blum Disruption of MHC Class II-Restricted Antigen Presentation by Vaccinia Virus J. Immunol., November 15, 2005; 175(10): 6481 - 6488. [Abstract] [Full Text] [PDF]

				S. Muraro, A. Bondanza, M. Bellone, P. D. Greenberg, and C. Bonini Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses Blood, May 1, 2005; 105(9): 3596 - 3604. [Abstract] [Full Text] [PDF]

				J. D. Lewis, M. H. Shearer, R. C. Kennedy, and R. K. Bright Surrogate Tumor Antigen Vaccination Induces Tumor-Specific Immunity and the Rejection of Spontaneous Metastases Cancer Res., April 1, 2005; 65(7): 2938 - 2946. [Abstract] [Full Text] [PDF]